Literature DB >> 20538699

Systemic and intraplaque mediators of inflammation are increased in patients symptomatic for ischemic stroke.

Fabrizio Montecucco1, Sébastien Lenglet, Angèle Gayet-Ageron, Maria Bertolotto, Graziano Pelli, Domenico Palombo, Bianca Pane, Giovanni Spinella, Sabine Steffens, Lizzia Raffaghello, Vito Pistoia, Luciano Ottonello, Aldo Pende, Franco Dallegri, François Mach.   

Abstract

BACKGROUND AND
PURPOSE: The concept of "vulnerable plaque" has been extended to the more recent definition of the "cardiovascular vulnerable patient," in which "intraplaque" and "systemic" factors contribute to the cumulative risk of acute cardiovascular events. Thus, we investigated the possible role of systemic and intraplaque inflammation in patients asymptomatic versus symptomatic for ischemic stroke.
METHODS: Regions upstream and downstream the blood flow were isolated from internal carotid plaques of patients asymptomatic (n=63) or symptomatic (n=18) for ischemic stroke. Specimens were analyzed for lipid, collagen, macrophage, lymphocyte, neutrophil, mast cell and smooth muscle cell content, and chemokine and cytokine mRNA expression. Chemokine receptors and adhesion molecules were assessed on circulating leukocytes by flow cytometry. Systemic inflammatory markers and biochemical parameters were measured on total blood, plasma, and serum.
RESULTS: Tumor necrosis factor-alpha and CCL5 serum levels as well as intercellular adhesion molecule-1 expression on circulating neutrophils were increased in symptomatic as compared with asymptomatic patients. Collagen content and smooth muscle cell infiltration were decreased in symptomatic plaques. In upstream regions of symptomatic plaques, lipid content and lymphocyte infiltration were increased. In downstream regions of symptomatic plaques, macrophage, neutrophil, and mast cell infiltration were increased. Intraplaque collagen content was positively correlated with smooth muscle cell infiltration and inversely correlated with macrophages, neutrophils, or serum tumor necrosis factor-alpha. Collagen reduction in downstream regions and serum tumor necrosis factor-alpha were independently associated with the likelihood of being symptomatic.
CONCLUSIONS: Inflammatory mediators are increased in ischemic stroke. Despite statistically significant, the correlation between tumor necrosis factor-alpha serum level and intraplaque vulnerability was weak and probably of limited biological importance.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20538699     DOI: 10.1161/STROKEAHA.110.578369

Source DB:  PubMed          Journal:  Stroke        ISSN: 0039-2499            Impact factor:   7.914


  31 in total

Review 1.  Pathophysiology and Treatments of Oxidative Injury in Ischemic Stroke: Focus on the Phagocytic NADPH Oxidase 2.

Authors:  Federico Carbone; Priscila Camillo Teixeira; Vincent Braunersreuther; François Mach; Nicolas Vuilleumier; Fabrizio Montecucco
Journal:  Antioxid Redox Signal       Date:  2014-04-22       Impact factor: 8.401

2.  Myelin specific cells infiltrate MCAO lesions and exacerbate stroke severity.

Authors:  Xuefang Ren; Kozaburo Akiyoshi; Marjorie R Grafe; Arthur A Vandenbark; Patricia D Hurn; Paco S Herson; Halina Offner
Journal:  Metab Brain Dis       Date:  2011-10-12       Impact factor: 3.584

3.  The activation of the cannabinoid receptor type 2 reduces neutrophilic protease-mediated vulnerability in atherosclerotic plaques.

Authors:  Fabrizio Montecucco; Vincenzo Di Marzo; Rafaela F da Silva; Nicolas Vuilleumier; Luciano Capettini; Sébastien Lenglet; Sabrina Pagano; Fabiana Piscitelli; Silvia Quintao; Maria Bertolotto; Graziano Pelli; Katia Galan; Lucie Pilet; Kristina Kuzmanovic; Fabienne Burger; Bianca Pane; Giovanni Spinella; Vincent Braunersreuther; Angèle Gayet-Ageron; Aldo Pende; Giorgio Luciano Viviani; Domenico Palombo; Franco Dallegri; Pascale Roux-Lombard; Robson A S Santos; Nikos Stergiopulos; Sabine Steffens; François Mach
Journal:  Eur Heart J       Date:  2011-11-22       Impact factor: 29.983

4.  Serum Levels of Thioredoxin Are Associated with Stroke Risk, Severity, and Lesion Volumes.

Authors:  Meng-Hai Wu; Fang-Yu Song; Li-Ping Wei; Zhao-Yun Meng; Zhi-Qiang Zhang; Qin-De Qi
Journal:  Mol Neurobiol       Date:  2014-12-19       Impact factor: 5.590

Review 5.  Immunological aspects of atherosclerosis.

Authors:  S Garrido-Urbani; M Meguenani; F Montecucco; B A Imhof
Journal:  Semin Immunopathol       Date:  2013-11-09       Impact factor: 9.623

6.  EphA1 Activation Induces Neuropathological Changes in a Mouse Model of Parkinson's Disease Through the CXCL12/CXCR4 Signaling Pathway.

Authors:  Jianjun Ma; Zhidong Wang; Siyuan Chen; Wenhua Sun; Qi Gu; Dongsheng Li; Jinhua Zheng; Hongqi Yang; Xue Li
Journal:  Mol Neurobiol       Date:  2020-10-15       Impact factor: 5.590

7.  Neutrophil migration towards C5a and CXCL8 is prevented by non-steroidal anti-inflammatory drugs via inhibition of different pathways.

Authors:  Maria Bertolotto; Paola Contini; Luciano Ottonello; Aldo Pende; Franco Dallegri; Fabrizio Montecucco
Journal:  Br J Pharmacol       Date:  2014-07       Impact factor: 8.739

8.  Combination of rosuvastatin and probucol inhibits MMP-9 expression via upregulation of miR-497 in cultured HUVECs and apoE knockout mice.

Authors:  Yuan-Yuan Wang; Hui Li; Xing-Hua Wang; Meng Yuan; Guang-Ping Li
Journal:  J Thromb Thrombolysis       Date:  2016-05       Impact factor: 2.300

9.  Cerebral ischemia initiates an immediate innate immune response in neonates during cardiac surgery.

Authors:  Selma O Algra; Kathelijne M Groeneveld; Alvin W L Schadenberg; Felix Haas; Fabiola C M Evens; Jenny Meerding; Leo Koenderman; Nicolaas J G Jansen; Berent J Prakken
Journal:  J Neuroinflammation       Date:  2013-02-07       Impact factor: 8.322

10.  Multimarker approach in discriminating patients with symptomatic and asymptomatic atherosclerotic carotid artery stenosis.

Authors:  Piotr Musialek; Wieslawa Tracz; Lukasz Tekieli; Piotr Pieniazek; Anna Kablak-Ziembicka; Tadeusz Przewlocki; Ewa Stepien; Przemyslaw Kapusta; Rafal Motyl; Jakub Stepniewski; Anetta Undas; Piotr Podolec
Journal:  J Clin Neurol       Date:  2013-07-01       Impact factor: 3.077

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.